Michael Lotze, MD

Summary

Dr. Lotze's primary area of research is broadly in tumor immunology, particularly the role of cellular therapy using dendritic cells, T cells, and NK cells. His current research interests include the further identification of clinical biomarkers and surrogates in the setting of cancer, the role of cell death pathways and autophagy, the nuclear protein high molecular group B1 [HMGB1] and other Damage Associated Molecular Pattern Molecules [DAMPs] in tissue injury, repair, and cancer. He is currently preparing major reviews on the role of costimulation as part of the therapeutic approach to cancer, integrating cancer biology and tumor immunology.